Venrock Healthcare Capital Par Acquires 73,649 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par purchased 73,649 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were purchased at an average price of $9.29 per share, with a total value of $684,199.21. Following the completion of the acquisition, the insider now directly owns 5,086,445 shares in the company, valued at $47,253,074.05. The trade was a 1.47 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Monday, February 10th, Venrock Healthcare Capital Par acquired 4,137 shares of KalVista Pharmaceuticals stock. The stock was purchased at an average price of $9.14 per share, for a total transaction of $37,812.18.
• On Monday, February 3rd, Venrock Healthcare Capital Par bought 14,562 shares of KalVista Pharmaceuticals stock. The shares were purchased at an average price of $9.22 per share, with a total value of $134,261.64.
• On Thursday, January 30th, Venrock Healthcare Capital Par purchased 43,707 shares of KalVista Pharmaceuticals stock. The shares were acquired at an average price of $8.76 per share, for a total transaction of $382,873.32.

KalVista Pharmaceuticals Trading Up 0.6 %

Shares of KalVista Pharmaceuticals stock opened at $9.33 on Thursday. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.30 and a 12 month high of $16.88. The firm has a market capitalization of $461.09 million, a P/E ratio of -2.56 and a beta of 0.85. The business has a fifty day simple moving average of $8.74 and a two-hundred day simple moving average of $10.58.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.01. Analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

KALV has been the topic of a number of recent analyst reports. TD Cowen assumed coverage on KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price objective on the stock. JMP Securities initiated coverage on shares of KalVista Pharmaceuticals in a report on Friday, January 31st. They issued an “outperform” rating and a $19.00 price target on the stock. Bank of America initiated coverage on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They set a “buy” rating and a $22.00 price objective on the stock. Citizens Jmp raised shares of KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 31st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, KalVista Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $23.80.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Martin Worley Group purchased a new stake in shares of KalVista Pharmaceuticals in the 4th quarter worth approximately $86,000. China Universal Asset Management Co. Ltd. boosted its holdings in KalVista Pharmaceuticals by 24.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock worth $87,000 after acquiring an additional 2,043 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of KalVista Pharmaceuticals by 10.0% in the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after acquiring an additional 1,319 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of KalVista Pharmaceuticals during the third quarter valued at $126,000. Finally, AlphaQuest LLC raised its position in shares of KalVista Pharmaceuticals by 17.1% in the 4th quarter. AlphaQuest LLC now owns 17,700 shares of the specialty pharmaceutical company’s stock worth $150,000 after purchasing an additional 2,588 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).